OTC · ALNAQ
Allena Pharmaceuticals, Inc.
Healthcare · Biotechnology
$0.00
Down-$0.00 (-99.01%)
Updated Aug 25, 2026, 12:35 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 122
- P/E ratio
- -0.07
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 16.45K
- Avg. volume
- 22.41K
Price performance
ALNAQ price history
1M range · 0 trading sessions · Daily adjusted prices
ALNAQ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ALNAQ news
The latest Smart Investors Daily articles mentioning ALNAQ.
Stock researchCompany · Overview
ALNAQ research
Overview
Company profile and research snapshot.
Company profile
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
